Form 4: Jazz Pharmaceuticals EVP Robert Iannone Reports Stock Sale
SEC Form 4
Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals, reported the sale of 2,403 ordinary shares on March 10, 2025.
Summary
- Robert Iannone, an EVP at Jazz Pharmaceuticals, sold 2,403 ordinary shares of the company on March 10, 2025.
- The shares were sold at a price of $138.4122 per share.
- Following the transaction, Iannone directly owns 79,621 ordinary shares of Jazz Pharmaceuticals.
Sentiment
Score: 5
Explanation: Neutral. This is a standard Form 4 filing indicating a stock sale by an executive. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a routine disclosure of an insider transaction. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, although it is a common practice.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of transaction: Robert Iannone sold 2,403 ordinary shares. |
| 03/12/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.